Frances M. Richards

10.9k total citations · 2 hit papers
71 papers, 5.1k citations indexed

About

Frances M. Richards is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Frances M. Richards has authored 71 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 29 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Frances M. Richards's work include Cancer, Hypoxia, and Metabolism (17 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Epigenetics and DNA Methylation (11 papers). Frances M. Richards is often cited by papers focused on Cancer, Hypoxia, and Metabolism (17 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Epigenetics and DNA Methylation (11 papers). Frances M. Richards collaborates with scholars based in United Kingdom, United States and Germany. Frances M. Richards's co-authors include Kevin G. Peters, Duncan I. Jodrell, Eamonn R. Maher, Chiara Fornari, Jo L. Bramhall, Giovanni Y. Di Veroli, Nabeel A. Affara, Dennis Wang, Séverine Mollard and Paul A. Crossey and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Annual Review of Biochemistry.

In The Last Decade

Frances M. Richards

71 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemical Cross-Linking: Reagents and Problems in Studies of Membrane Structure

1977 514 citations Frances M. Richards et al. profile →
Combenefit: an interactive platform for the analysis and visualization of drug combinations

2016 493 citations Giovanni Y. Di Veroli, Chiara Fornari et al. profile →

Peers

Countries citing papers authored by Frances M. Richards

Since Specialization

Citations

This map shows the geographic impact of Frances M. Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances M. Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances M. Richards more than expected).

Fields of papers citing papers by Frances M. Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances M. Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances M. Richards. The network helps show where Frances M. Richards may publish in the future.

Co-authorship network of co-authors of Frances M. Richards

This figure shows the co-authorship network connecting the top 25 collaborators of Frances M. Richards. A scholar is included among the top collaborators of Frances M. Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frances M. Richards. Frances M. Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma 2023 ·Journal for ImmunoTherapy of Cancer ·Vincenzo Graziano, Andreas Dannhorn, Heather Hulme, (unknown), (unknown), Saadia A. Karim, Matthew E. Wilson, (unknown), Brajesh P. Kaistha, Sabita Islam, James Thaventhiran, Frances M. Richards, Richard J. A. Goodwin, Rebecca Brais, Jennifer P. Morton, Simon J. Dovedi, Alwin G. Schuller, Jim Eyles, Duncan I. Jodrell	10
2	Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites 2019 ·EBioMedicine ·(unknown), Vijayalakshmi Kari, (unknown), Feda H. Hamdan, (unknown), (unknown), Jochen Gaedcke, Julia Kitz, Duncan I. Jodrell, Frances M. Richards, Christian Pilarsky, (unknown), Petra Rümmele, Thomas Knösel, Elisabeth Heßmann, Volker Ellenrieder, Steven A. Johnsen, Albrecht Neeße	24
3	Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine 2018 ·Cancer Research ·Siang‐Boon Koh, Yann Wallez, (unknown), Sandra Bernaldo de Quirós Fernández, Tashinga E. Bapiro, Frances M. Richards, Duncan I. Jodrell	28
4	The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression 2018 ·Molecular Cancer Therapeutics ·Yann Wallez, (unknown), Timothy Isaac Johnson, Siang‐Boon Koh, Chiara Fornari, James Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards, Duncan I. Jodrell	79
5	Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy 2017 ·PLoS Computational Biology ·Robert Jackson, Giovanni Y. Di Veroli, Siang‐Boon Koh, Ian S. Goldlust, Frances M. Richards, Duncan I. Jodrell	8
6	CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus 2015 ·Cancer Research ·Siang‐Boon Koh, Aurélie Courtin, (unknown), Robert G. Boyle, Frances M. Richards, Duncan I. Jodrell	48
7	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo 2014 ·British Journal of Cancer ·(unknown), (unknown), Aurélie Courtin, (unknown), Basetti Madhu, Natalie Cook, Albrecht Neeße, John R. Griffiths, (unknown), Duncan I. Jodrell, Frances M. Richards	17
8	Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes 2013 ·Chemistry & Biology ·(unknown), Frances M. Richards, Andreas Bender, Peter J. Bond, Oliver Korb, (unknown), (unknown), Paul Owen, R. M. Myers, Jordan W. Raff, Fanni Gergely, Duncan I. Jodrell, Steven V. Ley	92
9	Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells 2012 ·British Journal of Cancer ·Yao Lin, Frances M. Richards, (unknown), Jo L. Bramhall, Jennifer Harrington, Tashinga E. Bapiro, Avril A. B. Robertson, Daniella Zheleva, Duncan I. Jodrell	28
10	A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy 2011 ·Cancer Chemotherapy and Pharmacology ·Tashinga E. Bapiro, Frances M. Richards, Mae A. Goldgraben, Kenneth P. Olive, Basetti Madhu, Kristopher K. Frese, Natalie Cook, Michael A. Jacobetz, Donna-Michelle Smith, David A. Tuveson, John R. Griffiths, Duncan I. Jodrell	47
11	Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae 2010 ·Xenobiotica ·W. Alderton, Stéphane Berghmans, Paul Butler, (unknown), Angeleen Fleming, Zoe Golder, Frances M. Richards, I. Gardner	94
12	Prediction Of Ophthalmic Effects In Man By Screening Drugs For The Optokinetic And Optomotor Responses In Zebrafish 2006 ·Investigative Ophthalmology & Visual Science ·Frances M. Richards, (unknown), Paul Butler, Gareth Waldron, (unknown), (unknown), A. Fleming	2
13	Identification of novel VHL targets that are associated with the development of renal cell carcinoma 2006 ·Oncogene ·Mahera Abdulrahman, Esther N. Maina, Mark R. Morris, Malgorzata Zatyka, Raju R. Raval, Rosamonde E. Banks, Michael S. Wiesener, Frances M. Richards, Claire M. Johnson, Farida Latif, Eamonn R. Maher	17
14	Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma 2004 ·Journal of Clinical Pathology ·Mark R. Morris, Esther N. Maina, Neil V. Morgan, Dean Gentle, Dewi Astuti, Holger Moch, Takeshi Kishida, Masahiro Yao, Peter Schraml, Frances M. Richards, Farida Latif, Eamonn R. Maher	56
15	Molecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene 2001 ·Expert Reviews in Molecular Medicine ·Frances M. Richards	37
16	Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer 1999 ·Human Molecular Genetics ·Frances M. Richards, Shane McKee, M. Helen Rajpar, Trevor Cole, D. Gareth Evans, Janusz Jankowski, C. McKeown, D. S. A. Sanders, Eamonn R. Maher	251
17	An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel–Lindau Disease: Evidence for Modifier Effects 1998 ·The American Journal of Human Genetics ·Andrew R. Webster, Frances M. Richards, (unknown), Anthony T. Moore, Eamonn R. Maher	76
18	Somatic mutations of the von Hippel — Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma 1994 ·Human Molecular Genetics ·Keith Foster, Amanda Prowse, Anke van den Berg, Stewart Fleming, Miriam Hulsbeek, Paul A. Crossey, Frances M. Richards, Paul Cairns, Nabeel A. Affara, Malcolm A. Ferguson-Smith, (unknown), Eamonn R. Maher	307
19	Von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis 1993 ·Human Genetics ·Masahiro Yao, (unknown), Mary Lou Orcutt, Igor Kuzmin, Thomas Stackhouse, (unknown), Kálmán Tory, (unknown), Frances M. Richards, Eamonn R. Maher, Sal LaForgia, Kay Huebner, Denis Le Paslier, (unknown), Michael I. Lerman, Berton Zbar	46
20	Taql and Pstl RFLPs in the von Hippel–Lindau disease gene (VHL) 1993 ·Human Molecular Genetics ·Frances M. Richards, Farida Latif, Michael I. Lerman, B. Zbar, Eamonn R. Maher	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact